CytoReason and Pfizer agree deal worth up to $110M for AI drug discovery and development
Sept. 20 Quick Takes: Rocket gains gene therapy via Renovacor takeout
CytoReason announces expanded collaboration with Pfizer
CytoReason and Pfizer ink $110 million AI deal
CytoReason’s AI Earns Pfizer Extension Deal
CytoReason Announces Expanded Collaboration Deal with Pfizer
Data-crunching specialist CytoReason signs $110m Pfizer alliance
Pfizer Builds On AI/ML Pact With CytoReason With New Five-Year Deal
Pfizer to further tap CytoReason’s AI technology for drug discovery in up to $110M deal
What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
